SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (562)10/31/2003 6:15:57 AM
From: Icebrg  Read Replies (1) of 1022
 
THE PRODUCTION OF RECOMBINANT PHARMACEUTICAL PROTEINS IN PLANTS

Julian K-C. Ma1, Pascal M. W. Drake1 & Paul Christou2 about the authors

1 Department of Infectious Diseases, St. George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK.
2 Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Grafschaft, Auf dem Aberg 1, 57392 Schmallenberg, Germany.

correspondence to: Julian K-C. Ma jma@sghms.ac.uk

Imagine a world in which any protein, either naturally occurring or designed by man, could be produced safely, inexpensively and in almost unlimited quantities using only simple nutrients, water and sunlight. This could one day become reality as we learn to harness the power of plants for the production of recombinant proteins on an agricultural scale. Molecular farming in plants has already proven to be a successful way of producing a range of technical proteins. The first plant-derived recombinant pharmaceutical proteins are now approaching commercial approval, and many more are expected to follow.....

nature.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext